about
The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis ProjectRare coding variants in the phospholipase D3 gene confer risk for Alzheimer's diseaseGenome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseLarge meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's diseaseThe branched-chain aminotransferase proteins: novel redox chaperones for protein disulfide isomerase--implications in Alzheimer's diseaseUntargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's diseaseGenetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's diseaseCommon variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's diseaseCan commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer's and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink.Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's diseaseThe association of angiotensin-converting enzyme with biomarkers for Alzheimer's diseaseMetabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's DiseaseCore outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations.The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease.Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project.Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation.Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease.Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stageTumour necrosis factor-α (TNF-α) and miRNA expression in frontal and temporal neocortex in Alzheimer's disease and the effect of TNF-α on miRNA expression in vitroBIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging.Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patientsVascular genetic factors and human longevity.Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease.Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging.A multi-center study of ACE and the risk of late-onset Alzheimer's diseaseA randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocolAbeta-degrading enzymes in Alzheimer's disease.VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro.Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta.Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathologyThe sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project.Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia.Pathophysiology of white matter perfusion in Alzheimer's disease and vascular dementia.Aluminum in the diet and Alzheimer's disease: from current epidemiology to possible disease-modifying treatment.Aβ-degrading enzymes: potential for treatment of Alzheimer disease.Drug repositioning for Alzheimer's disease.Using Alzgene-like approaches to investigate susceptibility genes for vascular cognitive impairment.
P50
Q21261508-31DDA14F-47C9-4B62-ADC7-96997A8D03B2Q24312938-117AA090-7BB4-4F4F-B293-F7A5605626BAQ24612662-C631650F-229E-42E6-88E8-12431B22C024Q26810028-F79C571D-3142-46E6-8F55-5B516AF060D6Q28299806-50C89E1B-1465-49A7-BDC6-1FBBFC575C2AQ28544957-181711D4-4B28-47E9-952B-F2D84F0F6680Q28748461-92F41173-9F47-436A-9D81-16879B9F257DQ29614879-991A9AD8-22F1-4139-8C5D-CE650E4DF87CQ30490505-3A580A6C-DE98-469B-BFB3-0D5EF42BE554Q33526360-A1E4B10A-C4DD-4B39-B0E8-E460BEBFA688Q33821846-45B1CE00-DC78-4664-BD90-C08CDB71A5FDQ33844975-3D9BCCCC-5BB4-4F39-806A-F3D40AFAE000Q33852962-5BCAB0E2-184D-4D9D-BA3C-0FB023771C46Q33986970-D8E37736-0C5D-4FC5-B018-4200CD23EF40Q34136082-BF32994F-D0C3-48CF-8CA2-7C0313D8055DQ34304403-129FEB23-11B2-40E4-AE52-F06C7E93C4C3Q34312186-E6C0C9E3-04F2-4975-A35A-06F7E078B3ACQ34471903-8A5030CD-2C3A-48A0-8361-CE236E803ECDQ34663576-0FF899D4-9482-48AC-BBFF-4E05F7738654Q35031990-3F24A5A7-C175-4767-AF7D-51224CE0E3E8Q35036731-F75EEA6E-9496-4E30-9672-CCE7E919828CQ35201107-8D6D5E8C-A640-4B90-B754-B39206A50FD4Q35688006-764795D8-DC48-4B38-8C24-F4A9D4F2AC4EQ36300486-A620B859-8B2E-4525-AE6D-0A15E0F111ECQ36576477-B3B0E32E-2856-4A1E-AB92-A5C10EA81B01Q36670162-2ECA558C-7B0A-4090-A1C6-971E7E9F124DQ36847601-10E5C87D-78DE-40F4-9DC9-1B600BB5B063Q37106589-FDC54DB6-4B2E-4419-AF97-6B1D0C9B1DDFQ37118130-4F00F6D7-7F17-4F47-9E33-0973159A33A0Q37149053-D28516BB-B736-49AB-A3B5-91096E869D15Q37257169-D694DEFA-720A-4823-B4F4-E2238D77F4BBQ37348489-7C977A22-4494-4CD1-8A06-81D15CFEAEB7Q37440125-5FB54773-34EB-44FA-819E-39A031408F20Q37493067-5A088492-783A-470E-94E6-4D502DCE8D21Q37616474-A8C808F3-82CD-4E94-8188-409BEA006E3CQ37723412-CE360675-D88A-4EB4-B709-A9D64BDEFE7AQ37727742-39CB9429-B30E-4EFF-8C89-309C728D2237Q37946240-AF494DD7-5EFE-42B9-9811-B26E7FF3BB24Q38057607-46A7BF0A-548B-4719-95E6-A2A3B90B181CQ38063045-AFA7EC6F-5F6D-4C4A-8B60-9198B3D9AF3C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Patrick G. Kehoe
@ast
Patrick G. Kehoe
@en
Patrick G. Kehoe
@es
Patrick G. Kehoe
@nl
Patrick G. Kehoe
@sl
type
label
Patrick G. Kehoe
@ast
Patrick G. Kehoe
@en
Patrick G. Kehoe
@es
Patrick G. Kehoe
@nl
Patrick G. Kehoe
@sl
altLabel
Patrick Kehoe
@en
prefLabel
Patrick G. Kehoe
@ast
Patrick G. Kehoe
@en
Patrick G. Kehoe
@es
Patrick G. Kehoe
@nl
Patrick G. Kehoe
@sl
P1053
P-8760-2018
P106
P1153
7006249660
P21
P31
P3829
P496
0000-0002-7542-1139